NCT00000972View on ClinicalTrials.gov

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

Not specified

Study Completion Date

April 30, 1992

Conditions
HIV InfectionsHIV Seronegativity
Interventions
BIOLOGICAL

MTP-PE/MF59

BIOLOGICAL

Env 2-3

Trial Locations (3)

14642

Univ. of Rochester AVEG, Rochester

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

981050371

UW - Seattle AVEG, Seattle

Sponsors

Collaborators (1)

Biocine
All Listed Sponsors
collaborator

Biocine

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000972 - A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 | Biotech Hunter | Biotech Hunter